Pharmaceutical Outsourcing: #NoGoingBack Why I Made the Pledge Date Published: May 26, 2021 Article In this Pharmaceutical Outsourcing feature, Signant Health’s Chief Marketing Officer Scott Connor argues why the industry can’t afford to lose the progress made during COVID-19. He details why the #NoGoingBack industry-wide social movement matters. Chaired by industry members across organizations, #NoGoingBack has shown that competitors can and should collaborate to help protect research and allow it to reach new levels. Read more on how the adoption of technology benefits the greater research, not just COVID-19 vaccines. Interested in joining the movement? Pledge your name by visiting: www.nogoingback.health. In this Pharmaceutical Outsourcing feature, Signant Health’s Chief Marketing Officer Scott Connor argues why the industry can’t afford to lose the progress made during COVID-19. He details why the #NoGoingBack industry-wide social movement matters. Chaired by industry members across organizations, #NoGoingBack has shown that competitors can and should collaborate to help protect research and allow it to reach new levels. Read more on how the adoption of technology benefits the greater research, not just COVID-19 vaccines. Interested in joining the movement? Pledge your name by visiting: www.nogoingback.health. Download Now Share: LinkedInTweet Recommended Resources Impact of COVID-19 on Clinical Trials Watch Now Webinar Article Innovations in Clinical Neuroscience: Articles on Pediatric and Orphan Disease Clinical Research Dr. Joan Busner, Signant’s Clinical Vice President and in-house expert on pediatric and orphan disease clinical trials, recently co-authored three... Download Now Do DCTs Still Offer Clinical Precision in Challenging Patient Populations? Watch Now Webinar